Author

Shengya Fu

Institutions: Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy

Observed institutions: Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy

ORCID: 0000-0002-3203-0699

Observed ORCID: 0000-0002-3203-0699

OpenAlex ID: A5040328245

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

2022 · Haoyue Hu, Yue Chen, et al. · Frontiers in Immunology · 121

Treatment and Survival Patterns of Primary Adenosquamous Carcinoma of the Liver: A Retrospective Analysis

2021 · Qiheng Gou, Shengya Fu, et al. · Frontiers in Oncology · 17

Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review

2021 · Shengya Fu, Ting Wang, et al. · Journal of Oncology Pharmacy Practice · 9

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer

2022 · Shengya Fu, Linjuan Li, et al. · Frontiers in Pharmacology · 2

Works count: 4

Citation count: 149

H-index: 3

I10-index: 2